JPMorgan Chase & Co. reiterated their hold rating on shares of Allogene Therapeutics (NASDAQ:ALLO) in a research note published on Wednesday morning, AnalystRatings.com reports. The firm currently has a $29.00 target price on the stock.
Several other research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Allogene Therapeutics from a buy rating to a hold rating in a research note on Monday, August 12th. William Blair reiterated a buy rating on shares of Allogene Therapeutics in a research note on Tuesday. BTIG Research initiated coverage on shares of Allogene Therapeutics in a research note on Friday, August 9th. They issued a buy rating and a $37.00 price objective on the stock. ValuEngine upgraded shares of Allogene Therapeutics from a sell rating to a hold rating in a research note on Friday, November 1st. Finally, Canaccord Genuity initiated coverage on shares of Allogene Therapeutics in a research note on Monday, November 4th. They issued a buy rating and a $36.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $36.11.
Allogene Therapeutics stock opened at $27.32 on Wednesday. The firm has a market cap of $3.37 billion and a PE ratio of -4.15. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.46 and a current ratio of 13.46. The firm’s 50 day moving average price is $27.85 and its two-hundred day moving average price is $28.07. Allogene Therapeutics has a twelve month low of $23.37 and a twelve month high of $33.96.
In other Allogene Therapeutics news, insider Alison Moore sold 48,827 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $32.11, for a total value of $1,567,834.97. Insiders own 36.50% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. grew its position in Allogene Therapeutics by 58.3% in the second quarter. BlackRock Inc. now owns 3,562,333 shares of the company’s stock worth $95,650,000 after acquiring an additional 1,312,056 shares in the last quarter. Vanguard Group Inc. grew its position in Allogene Therapeutics by 64.0% in the second quarter. Vanguard Group Inc. now owns 3,443,180 shares of the company’s stock worth $92,449,000 after acquiring an additional 1,343,459 shares in the last quarter. LLBH Private Wealth Management LLC grew its position in Allogene Therapeutics by 652.8% in the second quarter. LLBH Private Wealth Management LLC now owns 1,155,717 shares of the company’s stock worth $31,031,000 after acquiring an additional 1,002,199 shares in the last quarter. Nuveen Asset Management LLC bought a new stake in Allogene Therapeutics in the second quarter worth approximately $14,967,000. Finally, Wildcat Capital Management LLC bought a new stake in Allogene Therapeutics in the second quarter worth approximately $14,289,000. 54.48% of the stock is owned by institutional investors.
Allogene Therapeutics Company Profile
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.
See Also: Death Cross
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.